"Stopping early may mean missed opportunities to prevent heart attacks, kidney disease progression and other complications." Researchers say the results may help healthcare providers, insurers and policymakers identify patients who could benefit from additional support to remain on GLP-1 therapy over time, Sontha said
Across all groups, proportions in each weight category stabilized after 12 months, with small variations between months 12 and 24, suggesting long-term weight trajectories are largely set by one-year post-cessation
Schedule a free consultation with a weight loss expert
Semaglutide as a Cardiovascular Disease Modifier: Semaglutide belongs to the class of medications known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which have been found to offer cardioprotective effects beyond glycemic control
f , Pharmacokinetics of peptide 8 following subcutaneous administration in male CD1 mice
Kyle Simmons, PhD Oklahoma State University, ongoing research on GLP-1 agonists and reward systems Schacht, J.P